Article Content

Muscle relaxant use doubles in the United States. The use of skeletal muscle relaxants (SMRs) nearly doubled in the United States between 2005 and 2016, according to a study in the June 24 JAMA Network Open. The researchers found that 22% of the prescriptions were to adults over 65, despite SMRs being considered potentially inappropriate for this age group owing to significant central nervous system (CNS) adverse effects, such as dizziness and sedation, and limited evidence of their long-term efficacy. In visits for continuing a SMR prescription, 67% of patients also received an opioid, adding to the risks of serious drug interactions, amplified CNS effects, and possible overdose. Efforts to limit the long-term use of SMRs, their concomitant use with opioids, and use in people over 65 should be considered.